Adverse drug reactions among children with tuberculosis in China: a multicentre study, 2017–2022

Read full text Summarise with VIRAT
Authors: Yiqing Zhou, Yu Kan, Ping Liu, Hongmei Xu, Juan Ma, Haiyan Li, Xin Yu, Qingshan Cai, Man Tian, Qing Fang, Xianhui Zeng, Guangxu Yang
+4 more Tao Yang, Fei Wang, Bin Chen, Leonardo Martínez
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Although tuberculosis (TB) treatment, if adequately taken and adhered to, is highly effective. To investigate the occurrence, frequency and related factors of adverse drug reactions (ADRs) during anti-TB treatment in children in China. We conducted a multicentre study and collected data from 11 representative paediatric specialists and general hospitals offering anti-TB treatment. The outcome of interest was the occurrence of any ADRs. Multivariable logistic regression was performed to explore factors associated with ADRs and to identify groups at high-risk for ADRs. In total, 482 patients were enrolled; of whom, 94 (19%) reported an ADR. The most common ADRs were blood system damage (24%) and gastrointestinal reactions (24%). Most ADRs occurred within the intensive treatment period and were of short duration. Children with severe TB or those treated with HRZ(E) + second-line drugs in the intensive phase were at higher odds of developing ADRs (OR = 2.44, 95% CI: 1.36–4.39, p = 0.003; OR = 3.70, 95% CI: 2.01–6.81, p < 0.001, respectively). ADRs are prevalent in Chinese paediatric TB patients, predominantly haematological or gastrointestinal, transient during the intensive phase. Severe disease and HRZ(E) + second-line regimens confer elevated risk, necessitating targeted surveillance and optimized paediatric therapies balancing efficacy and safety.

Fields of Study & Subjects

Tuberculosis Research and Epidemiology Pharmacovigilance and Adverse Drug Reactions Drug-Induced Adverse Reactions

Publication details

Journal / source
Figshare
Publication date
25 March 2026
Language
EN